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1. Introduction
The aim of this chapter is to present an overview of salient findings in human beings and
animal models (particularly in the chicken), as related to known participating molecules in
angiogenesis within the lung as a response to induced and natural environmental hypoxia, in
the framework of the pathobiology of pulmonary hypertension (PH).
Hypoxic PH is now recognized as an important disease within the PH types. More than 140
million human beings are settled in geographical zones located 2500 m above sea level
(Peñaloza and Arias, 2007). Animals which provide proteins for human consumption, have
different degrees of susceptibility to develop PH, especially the commercial chicken, which is
particularly prone to develop PH, either from hypoxia (Gómez et al., 2007, 2008; Vásquez and
Hernández, 2011; Areiza et al, 2011 and others) or low temperatures (Pakdel et al., 2005; Pan
et al., 2005). The chicken has been proposed as a model to study PH in humans (Al-Ruyabe et
al., 2010; Wideman and Hamal, 2011).
Exposure to hypoxia has been reported to cause different effects on the pulmonary vasculature.
These include increasing the extent of pulmonary vascular network, increased vascular tone,
vascular remodeling and in some cases quantitative reduction of microvessels. Neo-formation
of blood vessels in the lung, takes place through a mechanism not fully understood and often
controversial. Remodeling of pulmonary arterioles has been thoroughly studied. It includes
thickening of the medial muscle and adventitia layers. Many tasks have been directed to
discover the role of the endothelium in maintaining pulmonary vascular tone and in the PH
remodeling process. Endothelial dysfunction leads to chronically impaired production of
vasodilators such as nitric oxide (NO) and prostacyclin along with prolonged over expression
of vasoconstrictors such as endothelin-1 (ET-1). These changes affect vascular tone and
promote vascular remodeling. Given that most of these mediators affect the growth of smooth
muscle cells, an alteration in their production may facilitate the development of pulmonary
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vascular hypertrophy and structural remodeling, which are characteristic of PH (Budhiraja et
al., 2004; Humbert et al., 2004; reviewed by Hernández and Sandino de, 2011).
Both processes, angiogenesis and remodeling of pulmonary arterioles, appear to share the
participation of similar molecules. In fact, some of them, known to increase pulmonary blood
vessels tone during hypoxic exposure, are also involved in generating pulmonary blood
vessels. In this framework, three main research cellular targets can be identified: the endothe‐
lium, the smooth muscle cells of the wall of pulmonary arterioles and, adventitial connective
tissue cells.
PH  has  been  related  with  malfunction  of  potassium  channels  and  over-regulation  of
calcium channels  on  the  cell  membrane  of  vascular  muscle  cells  as  well  as  endothelial
dysfunction. The latter, as it pertains with decreasing NO and prostacyclin (vasodilators)
delivering  and  increment  of  vasocontrictors,  such  as  endothelin-1  (ET-1)  Inagami  et  al.,
1995; Voelkel and Tuder, 2000)
In adult subjects, angiogenesis could be taken as a compensatory process during hypoxic
exposure. This process would be in addition to the well-known mechanisms of augmenting
blood perfusion in less vascularized areas in the lung, hyperventilation and erythropoiesis.
Those areas might be a potentially available area for de novo vascular formation. Human beings
living in highlands, have developed a greater lung capacity through evolution, as an adaptive
mechanism to hypobaric hypoxia (Frisancho, 1970). Also, high landers show increased lung
capillary density than lowlanders, which was interpreted as an effect of hypoxia on angio‐
genesis (Bisschop et al, 2010).
Ooi et al (2000) and Howell et al (2002, 2003) determined that hypoxic hypoxia (10% oxygen)
provoked augmentation in volume and total length in pulmonary blood vessels in rats,
together with an increment in endothelial superficial area and cells numbers. In another work,
chronically hypoxic rats, which exhibited a greater degree of vascular development through
angiogenesis, had higher cardiac mass index values than the correspondent ones in animals
subjected to hypoxia and hypercapnia or normoxia (Howell et al., 2004). In mice subjected to
hypoxia, Pascaud et al (2003) gave evidence that inhibition of hypoxia-induced angiogenesis,
enhanced the degree of PH.
Angiogenesis is regulated by angiogenic and anti-angiogenic molecules (Pascaud et al., 2003;
Maharaj and D`Amore, 2007). Genetic and epigenetic factors permit blood vessels formation
(Pauling and Vu, 2004). Taraseviciene-stewart et al (2001) found that plexiform lesions in
idiopathic pulmonary hypertension (iPAH) were associated with disordered angiogenesis due
to exaggerated mitosis of endothelial cells. Tuder and Voelkel (2002) reported endothelial cell
proliferation in cases of primary PH, and, since these cells exhibited markers of angiogenesis,
the authors named this process a "disordered or misguided angiogenesis”. In this context,
endothelium progenitor cells are now claimed to be therapeutic targets in PH due to their
possible involvement in PH pathobiology. Nitric oxide synthases (eNOs), vascular endothelial
growth factor (VEGF), angiopoietins and their receptor tie-2, which are associated with
vascular remodeling, were all expressed in a monocrotaline induced model of PH (Cho et al.,
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2009). Furthermore, induced ischemia results in pronounced cell proliferation and consequent
lung vascularization in mice, within a period of 20 days (Wagner et al, 2006).
If vascular growth in the lung is an adapting mechanism to hypoxia, genetically predisposed
individuals will develop hypoxic PH, and have a diminished pulmonary vascular growth
capacity. Hence, angiogenesis might be the expression of genetic adaptation or predisposition
to PH inducers.
2. Angiogenic promoting factors
The hypoxia inducible factor (HIF) system is oxygen sensitive. It includes HIF-1 and HIF-2.
They bind and activate many of the same genes, but differ in their participation during
hypobaric hypoxia. For instance, HIF-2 alone is responsible for the liberation of erythropoietin
through stimulation of connective tissue cells in the kidney (Paliege et al., 2010) and other
hematological reactions to hypoxia (reviewed by Tissot van Patot and Gassmann, 2011). HIF-1
is a key molecule in regulating the expression of several angiogenic molecules. Among the
hypoxia-inducible genes which have important HIF-1 binding sites and are believed to
participate in the pathogenesis of PH and angiogenesis as well, are those encoding VEGF (Liu
et al., 1995), the VEGF receptor 1 (Gerber et al, 1997), and ET-1 (Hu et al., 1998). Expression of
VEGF and its receptor Fetal Liver Kinase 1 receptor (FLK-1) was enhanced in hypoxic pulmo‐
nary hypertensive rats (Christou et al., 1998). Rats maintained under hypoxic hypoxia
(exposure to 10% oxygen) showed augmented volume and total length of pulmonary blood
vessels (Howell et al. 2002, 2003; Ooi et al., 2000). In another study, rats exposed to hypobaric
hypoxia, exhibited reduced Angiopoietin-1/Tie2 and VEGF expression, together with a
diminished number of arterial blood vessels in the lung (Yamamoto et al., 2008).
Sands et al (2012) gave insight on the interaction of members of the VEGF family in hypoxic
PH. They found that VEGFB and the placental growth factor (PGF) inhibit or potentiate the
actions of VEGFA, according to their relative concentrations, which change in the lungs of rats
subjected to hypoxic hypoxia. The same authors stated that the abovementioned effects in
vivo depend on specific concentrations of VEGF and PGF within the alveolar wall during
adaptation to hypoxia. In this context, human subjects developing acute mountain sickness
had higher levels of plasma VEGF on ascend to altitude as compared to their own values
obtained under normoxic conditions. This variation did not occur in healthy subjects (Tissot
van Patot et al., 2005).
VEGF exerts its angiogenic effect through four different pathways, which include NO
participation (proposed by Gramatikoff, 1999). In a previous study, adrenomedullin mRNA
expression was greater in the lungs of chickens with pulmonary hypertension compared with
those without pulmonary hypertension (Gómez et al., 2008) and Vadivel et al (2010) demon‐
strated that adrenomedullin promotes angiogenesis in the lung. Hence, two vasodilators of
pulmonary blood vessels, NO and adrenomedullin, may also have angiogenic properties.
Fahra et al (2011) found that CD34(+) and CD133(+) progenitor cell numbers are higher in the
bone marrow, blood, and pulmonary arteries of pulmonary hypertensive subjects as compared
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to healthy controls. The blood levels of (hypoxia inducible myeloid-activating factors such as
erythropoietin, the stem cell factor (SCF), and hepatocyte growth factor (HGF) were higher
than normal levels in diseased individuals, and related to PH severity. Similarly, Davie et al
(2004) found that progenitor cells from bone marrow origin contribute to neo-vascularization
in pulmonary arteries of hypoxic calves, based on quantitative morphometric analyses of lung
tissue from normoxic and hypoxic individuals. Their results showed adventitial growth in
vasa vasorum of pulmonary arteries. This change was attributed to the transformation of cells
from the bone marrow, which would be mobilized into the circulation, and differentiate into
endothelial and smooth muscle cells. This model was supposed to entail an increase in the
expression of c-kit(+), VEGF, fibronectin, and thrombin, as responses to hypoxia.
PH is linked to myeloid abnormalities, some of which may be related to increased production
of HIF-inducible factors by a diseased pulmonary vasculature, but findings in non-affected
subjects, suggest that myeloid abnormalities may be intrinsic to the disease process. Pro-
angiogenic cell progenitors, and endothelial cells that have pathologic expression of hypoxia-
inducible factor 1 alpha (HIF-1 alpha), were shown to be quantitatively higher in PH bone
marrow, blood, and pulmonary arteries than in healthy controls. Also, the HIF-inducible
myeloid-activating factors erythropoietin, stem cell factor (SCF), and hepatocyte growth factor
(HGF) showed higher than normal levels in blood of pulmonary hypertensive subjects, and
related to disease severity (Samar et al., 2011). In addition, endothelial progenitor cells with
angiogenic capacity were found in the pulmonary circulation (Yoder, 2011). Epidermal growth
factor promotes both angiogenesis and vascular remodeling (Janakidevi et al., 1995; Toby et
al., 2010).
Bone morphogenetic protein (BMP) is compromised in endothelial repair within the pulmo‐
nary microvessels, and its expression is reduced in hypoxic PH, due to an increment in
endothelial cell-derived Gremlin 1 and Gremlin 2, which antagonize BMP 2 type receptor
expression (Cahill et al., 2012).
3. Inhibitors of angiogenesis
Angiogenesis is inhibited by thrombospondin-1 (TSP-1), a molecule produced by endothelial
cells. Its secretion is induced by hypoxia and, experimentally, by NO inhibitors. In mesangial
and smooth muscle cells, the cyclic guanosine monophosphate (GMPc) and kinase GMPc
dependent protein, negatively regulate TSP-1 expression. CD36, a TSP-1 receptor, inhibits
endothelial cell quimiotaxis (Isenberg el al., 2005). Low doses of NO stimulate endothelial cell
proliferation, their motility and adhesion to collagen I matrixes, but the opposite is true for
correspondent high doses. Exogenous TSP-1 treatment inhibits endothelial cell motility
(Isenberg et al., 2005) and suppresses the angiogenic response provoked by low dose NO
treatment (Ridnour et al., 2005).
Endogenous endostatin inhibits angiogenesis (Wickstrom et al., 2002; Paddenberg et al.,
2006); it blocks the G1 phase of the cell cycle in endothelial cells, the attachment of VEGF165
and VEGF121 to the receptor VEGFR2 (Ribatti, 2009), and triggers endothelial cell apoptosis
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(Dhanabal et al., 1999). Endostatin interferes with the assembly of the actin cytoskeleton of
endothelial cells and inhibits their proliferation and participation in angiogenesis (Abdollahi
et al., 2004; Skovseth et al., 2005). Endostatin expression on the surface of the smooth muscle
cells of pulmonary arterioles in the mouse, is provoked by hypoxic exposure (Paddenberg et
al., 2006). NO, in culture, induces endostatin production. Hence, endothelial apoptosis is also
induced (Deininger et al., 2003). In human endothelial cell cultures, addition of endostatin
reduces angiogenic activity by reducing HIF-1α, VEGF, VEGFR2, HGH and EGFR gene
expression. Furthermore, expression of some anti-angiogenic genes, such HIF1An (a HIF
antagonist), Kininogen, TSP-1 and a Vasostatin precursor is increased (Abdollahi et al., 2004).
However, it appears that the mode of action of endostatin, in this context, needs to be fully
elucidated (Deininger et al., 2003; Skovseth et al., 2005).
Adiponectin (ADPN) reinforces the vasodilatory action of NO in pulmonary blood vessels
(Summer et al, 2009), and as stated, if NO contributes to the control of angiogenesis, ADPN
will be a potential inhibitor of vascularization. Also, Le Cras et al (2003) found that alpha
transforming growth factor (TGF-α) overexpression induced a diminution in pulmonary
vascular development, which was accompanied by severe PH and vascular remodeling.
Oxidative stress is higher in the lungs of pulmonary hypertensive chickens (Iqbal y col., 2001a,
b), which has been associated, in another species, with decreasing numbers of blood vessels
(Murfee and Schmid-Schonbein, 2008). Oxidative stress, occurring in chronically hypoxic mice,
can enhance endostatin production (Deininger et al., 2003) (Paddenberg et al., 2006).
4. Highlights on vascular development under hypoxia or normoxia in the
chicken model
Angiogenesis in the mature pulmonary circulation could be a structural adaptation that may
have important beneficial consequences for gas exchange (Howell et al., 2003). In contrast,
Yamamoto et al (2008) reported a chronic hypoxia-induced pulmonary blood vessels loss, an
event sometimes called “rarefaction” or “pruning”.
Although there is no definitive evidence of less vascularized areas in the avian lung, it is
feasible that during hypoxia, vasculogenesis and angiogenesis occur to augment the gas
exchange area. Hypoxia exposure for 3 to 4 weeks, does not affect pulmonary growth in current
commercial chicken strains (Vásquez and Hernández, 2011; Areiza et al., 2011). These findings
appear to be controversial, since alveolar and vascular neo-formation should both increase in
the pulmonary response to hypoxia (reviewed by Bhattacharya, 2008). If this is not the case,
less vascularized areas within the lung could gain new blood vessels, which might not
significantly affect the whole organ´s weight. It should be noticed that arteriogenesis might
also play a role in neo-vascularization (Deindi and Schaper, 2008)
The final goal of angiogenesis in the lung, should be to construct a complete functional arterio-
venous tree. Therefore, vascular density would be represented by different types of blood
vessels, such as arterioles or pre-capillaries. In this framework, using the chicken as a model,
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quantitative and molecular studies were undertaken to test the potentiality of hypobaric
hypoxia to induce angiogenesis, to detect possible differences in vascular density in pulmonary
hypertensive chickens and to correlate these findings with mRNA expression of some key
genes for angiogenesis. Under hypobaric hypoxic conditions (altitude 2638 m above sea level,
(oxygen tension: approximately 111 mmHg), both, healthy and pulmonary hypertensive birds,
had more blood vessels with diameter ranges between >100-200, >200-300 and >300-500 µm,
as compared to healthy chickens maintained under relative, normobaric, normoxic conditions
(460 meters above sea level (oxygen tension: approximately 152 mmHg). However, the
opposite was encountered when comparing values obtained for blood vessels within the
≥50-100 µm range. Coincident with this result, decreased expression of hepatocyte growth
factor (HGF), HIF-2α, VEGF, Flk-1, and HGFR genes was encountered in the lung of chickens
exposed to hypoxia. The same mRNA expression pattern did not show coincidence with
observations for blood vessels within the range of 100-500 µm (Areiza et al., 2011, 2012).
It is interesting that the mRNA expression of various genes compromised in both, angiogenesis
and vascular remodeling, varies in pulmonary hypertensive (susceptible chickens) versus non-
pulmonary hypertensive chickens, which indicates different degrees of resistance or suscept‐
ibility to hypobaric hypoxia (Gómez et al, 2007, 2008; Areiza et al., 2012). This coincidence
reinforces the idea that among all the known compensatory mechanisms for low pO2 in the
airways and hypoxemia, angiogenesis is one of them, but it might be a long term one.
5. Final remarks
Promoting angiogenesis, vasculogenesis, or arteriogenesis could represent a possible palliative
treatment in individuals chronically exposed to hypobaric hypoxia. It is clear that it would be
useful to establish some characteristics of vascular development in the lung of susceptible
individuals subjected to chronic hypoxia, in order to design long term treatments, such as
vascular neo-formation enhancement. In this context, it is desirable to further investigate the
chronology of angiogenesis in the hypoxic lung.
Again, mesodermal derivatives particularly bone marrow cells, the endothelium, and fibro‐
blasts, act in two different but possibly complementary ways, as a response to hypoxia: the
remodeling process and pulmonary vascular neo-formation. However, as has been presently
highlighted, some results are controversial, which could not be currently explained, since there
is not enough information on the vascular development in the lung, as a result of hypoxic
exposure of susceptible and non-susceptible individuals, which would allow for the under‐
standing of the molecular framework of angiogenesis at different stages of development and
possibly, the correspondent genes involved.
Angiogenesis is a distinct mechanism to compensate for the hypoxic conditions within the
alveoli (or respiratory capillaries in birds). However, addition of new blood vessels to the lung
as a compensatory mechanism, might be a time-dependent process, as it occurs in the placenta,
where distinct factors intervene at different times during gestation (Hamilton et al., 1995;
Athanassiades and Lala, 1998; Matsumoto et al., 2002; Wulff et al., 2002), and further studies
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are needed in this matter. Evidence in this direction was given by Sands et al (2011), as related
to the adapting process to hypoxia. They found that the in vivo actions of VEGFB and PGF can
either inhibit or potentiate the actions of VEGFA. Those effects depend on their relative
concentrations within the lung, which change in the hypoxic lung.
At this point, it is noted that ET-1, one the most studied molecules, has been chosen as a target
molecule, in works aimed to design PH alleviation, by blocking its A receptor with bosentan
(Weber et al., 1996; Lim et al., 2009). Also, vasoactive intestinal peptide was found to be a more
potent ET-1 A receptor blocking agent than bosentan (Hamidi et al., 2011). Stromal derived
factor 1 (SDF1), angiopoietin 2 (ANGPT2), placental growth factor (PGF), platelet-derived
growth factor B (PDGFB), and stem cell factor (SCF) are also included as target molecules
(reviewed by Rey and Semenza, 2010).
It is clear that both, angiogenesis and vascular remodeling as seen in PH, share common
biological pathways and the endothelium appears to be the main participating structure in this
regard. This coincidence might be an advantage in the design of therapeutic measures.
Some apparent differences in quantitative findings related to vascular neo-formation appear
to depend on genetic differences and/or time of exposure to hypoxic conditions.
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